Integra LifeSciences Holdings Corp. (IART: Quote) Friday said it has received European CE Mark Certification for its Integra Flowable Wound Matrix, a device used for filling deep soft tissue or tunneling wounds in patients suffering from diabetes.
The device has been recognized by surgeons as one of the most innovative new products available for the management of chronic wounds in diabetic patients, thereby lowering the risk of amputation.
French Society of Reconstructive and Esthetic Plastic Surgery has awarded Integra's Flowable Wound Matrix 1st place in its innovation contest.
Approximately 55 million people in the European Union suffer from diabetes, of which an estimated 3 million will develop a foot ulcer.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org